Results of the man age ment of rec tal can cer have enor mously im proved over the last al most forty years, by the pro gres sive de vel op ment of new inte grated treat ment op tions. nev er the less an op timi za tion of the re sults is needed to raise the still sub-op ti mal out come in terms of sur vival. sev eral na tional and in ter na tional guide lines ad dress the best treat ment choice over all eval u at ing the ev idence ba sis avail able from lit er a ture. Still a cer tain de gree of dis agree ment is pres ent, par tic u larly about the pref er a ble pre op er a tive rt treat ment sched ule. ran dom ized tri als rep re sent the main land mark and most im por tant tool for the sci en tific sce nario: de fining a po ten tially es tab lished stan dard of care, or suggest ing the more prom is ing ap proach to fo cus the research into, thus ori ent ing the ef forts of cli ni cians and re search ers. This manu script will mainly fo cus on the ev i dences de rived from ran dom ized clin i cal trial describ ing the main is sues about the multimodal in tegrated treat ment for rec tal can cers. It will fo cus on both lo cally ad vanced (LA)/pri mary unresectable (UR), and resectable rec tal can cers; some non-random ized tri als of rel e vant the dis ser ta tion will also be men tioned
R e sults of the man age ment of rec tal can cer have enormously im proved over the last al most forty years, by the pro gres sive de vel op ment of new in te grated treat ment op tions 1, 2, 3 . In par tic u lar: the ex ploit of new sur gi cal tech niques (in the sur gi cal area of in ter est) 3, 4 , the evo lu tion of mod ern ra dio ther apy 5, 6 , of ten as so ci ated to chemosensibilization, the stan dard ized eval u a tion of sur gi cal spec i mens 7 , and the re cent ad van tages of proper non-in va sive ra dio log i cal im ag ing to better per form both stag ing and the eval u a tion of prognostical fea tures 8 over all did con trib ute to the stan dard qual ity-level for the in te grated treat ment of such tu mors. Nev er the less an op ti mi za tion of the re sults is needed to raise the still sub-op ti mal out come in terms of sur vival 9 . Sev eral Na tional and In ter na tional Guide lines ad dress the best treat ment choice over all eval u at ing the ev i dence ba sis avail able from lit er a ture. Still a cer tain degree of dis agree ment is pres ent, par tic u larly about the pref er a ble pre op er a tive RT treat ment sched ule 2 . Ran dom ized tri als rep re sent the main land mark and most im por tant tool for the sci en tific sce nario: de fin ing a po ten tially es tab lished stan dard of care, or sug gest ing the more prom is ing ap proach to fo cus the re search into, thus ori ent ing the ef forts of cli ni cians and re search ers. On the other hand, new par a digms of ap proach are cur rently under def i ni tion and evo lu tion, that chal lenge and si mul taneously in te grate the use of ran dom ized clin i cal tri als (RCT), as the al ways wider use of rapid learn ing machines, and the in ves ti ga tion of surrogated end points 9 . Any way in or der to sum ma rize the main ev i dences on the cur rent knowl edge about the treat ment of rec tal can cers, it is im per a tive to re fer to RCTs, also to ad dress fur ther stud ies on the more ev i dent and ur gent con tro ver sies. Aims of this pa per is to re view the main is sues about the multimodal in te grated treat ment for rec tal can cers fo cusing on both lo cally ad vanced (LA)/pri mary unresectable (UR), and resectable rec tal can cers.
MA TE RI ALS AND METH ODS
The manu script will mainly fo cus on the ev i dences derived from RCT; some non-ran dom ized tri als of rel e vant the dis ser ta tion will also be men tioned. Is sues de scribed will in clude: the role of ra dio ther apy (RT) among in te grated treat ments; the mod i fi ca tion of inte grated ap proach re plac ing the post op er a tive RT with pre op er a tive RT; the de bate on the choice be tween short course RT (SCRT) and long course radiochemotherapy (LCRTCT); the new chal lenges for the op ti mi za tion of the drugs as so ci ated into the LCRTCT reg i mens; the mod u la tion of sur gi cal ap proach af ter pre op er a tive RT; the im por tance of the in volve ment of cir cumfer ential mar gins (CM).
DIS SER TA TION Lo cally Ad vanced and Pri mary Unresectable Tu mors
What tu mor type be longs to the unresectable pre sen tations is a quite clear and ob jec tive con cept; on the other hand, the lo cally ad vanced pre sen ta tions het er o ge neously in clude both le sions with a tough mar gin for at tempt ing a re sec tion (even tu ally de fined with the aid of clin i cal evalu a tion), and fixed le sions in vad ing struc tures close to the rec tum 10 . Not clearly upfront-resectable pre sen ta tions also in clude: the threat en ing or in fil tra tion of mesorectal fas cia (MRF) or the di rect in volve ment of the sphincter (see also be low).
In gen eral the com mon stan dard of treat ment for T4 and/or lo cally unresectable (in clud ing lo cally re cur rent) rec tal can cers is rep re sented by LCRTCT with a 5-Fluoruracil (5-Fu)-based reg i men 11 . The ran dom ized trial pub lished by Braendengen et al.
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on pa tients with unresectable or re cur rent le sions ad dressed this is sue. They ran dom ized 98 pa tients to ei ther RT alone (50Gy) or to con cur rent LCRTCT with 5-Fu-based sched ule (up to the same to tal RT dose), fol lowed by sur gery and postop er a tive chemoterapy. Adjuvant che mo ther apy was allowed for pa tients in the RT-only arm, if in Stage III. Clin i cal out comes sig nif i cantly fa vored the com bined treat ment arm. The LCRTCT arm re ported higher rates of R0 re sec tions (84% vs. 68%; p = 0.009) and lower rates of lo cal fail ure (67% vs 82%; p = 0.03). It failed to increase the OS al though a trend was re ported (66% vs. 53%; p = 0.09).
A RCT lead by north Eu ro pe ans groups, de fined by the ac ro nyms "RAPIDO" trial, is cur rently en roll ing pa tients pre sent ing fea tures of high risk fea tures for lo cal or systemic fail ure, in clud ing: cT4b, N2, MRF in volve ment, ex tra mu ral vas cu lar in va sion 13 . The pro to col ran dom izes se lected pa tients into a SCRT (25Gy in 5 frac tions) followed by se quen tial pre op er a tive che mo ther apy (CT) and then sur gery, or into a sched ule of LCRTCT (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) fol lowed by sur gery and then adjuvant CT with the same reg i men of the first arm (but ad min is trated for lon ger pe riod). The pri mary ob jective of the study is to an a lyze the dis ease free sur vival at 3 years. The in ter est to com pare such ap proaches in this sub set of pa tients is to eval u ate the po ten tial of pre op er ative CT added to an RT sched ule shorter than the common stan dard to both eval u ate the po ten tial wider use of SCRT, and to ear lier de liver sys temic ther apy in pa tients at high risk for dis tant re lapses. The aim of on go ing RAPIDO trial is to test if add ing SCRT to se quen tial neoadjuvant che mo ther apy can im prove both the outcomes of sur vival end points, and the suboptimal rates of patho log i cal com plete re sponses (pCR) af ter pre op er a tive treat ment usu ally as so ci ated to SCRT.
For pa tients ex press ing ad e quate re sponses, the wid est pos si ble re sec tion re mov ing the ini tially in fil trated organs should be con sid ered 11 . For se lected pre sen ta tion, intraoperative RT (IORT) or brachytherapy (BRT) is po ten tially in di cated to im prove out comes 11, 14, 15 .
Resectable Tu mors

Role of Post op er a tive Ra dio ther apy in the Clin i cal In tegrated Man age ment
His tor i cally, the adjuvant as so ci a tion of RT af ter surgery has been ap plied to im prove clin i cal out comes with en cour ag ing re sults 16 . The po ten tial ad van tages of the avail abil ity of patho log i cal stag ing to as sess the need for fur ther ther a pies to im prove the clin i cal out come fol lowing sur gery, is the ma jor point of strength for such approach.
At least 5 im por tant ran dom ized tri als an a lyzed the impact of RT (not com bined with chemosensibilization) after sur gery 16, 17, 18, 19, 20 . Even though none re vealed a signif i cant sur vival im prove ment, both the NSABP R-01 20 , and the MRC 19 tri als showed a sig nif i cant im prove ment of lo cal con trol over sur gery-only arms. Some RCTs later con firmed the su pe ri or ity of the con com i tant use of radiochemotherapy (RTCT) in the adjuvant set ting. Krook et al. 21 did ran dom ize 204 pa tients with rec tal carci noma ("ei ther deeply in va sive or met a static to re gional lymph nodes") to post op er a tive RT alone (4500-5040 cGy) or to RT plus 5-Fluorouracil, which was both preceded and fol lowed by a cy cle of sys temic ther apy with 5-Fluorouracil plus Semustine (Methyl-CCNU).
The Na tional In sti tutes of Health (NIH) Con sen sus Con fer ence of 1990, stated the adjuvant use of RTCT after sur gery for pT3 and/or N1-2 rec tal can cers as stan dard in USA
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. In 1994 the RCT pub lished by O'Connel et al. con firmed the use of pro tracted ve nous in fu sion (PVI) of 5-Fu con com i tantly with RT af ter cu ra tive sur gery: that be came the stan dard as so ci a tion for adjuvant RTCT 23 . In this four-arms ran dom ized trial, 660 pa tients with lo cally ad vanced resectable rec tal can cer re ceived in ter mit tent bolus in jec tions or PVI of 5-Fu dur ing post op er a tive RT. They also re ceived sys temic che mo ther apy with Semustine plus 5-Fu or with 5-Fu alone in a higher dose, ad min is tered be fore and af ter the pel vic ir ra di a tion. Patients who re ceived PVI 5-Fu (225 mg/m 2 /day; 7 days/week) had a sig nif i cantly in creased time to re lapse (p= 0.01) and im proved sur vival (p=0.005).
Thus pre sent ing po ten tial ad van tages, and hav ing showed a ben e fit over sur gery alone, post op er a tive ra diother apy (ei ther as so ci ated to chemosensibilitazion or not) have some draw backs: the most im por tant are related to the higher rates of tox ic ity re spect to the pre op era tive set ting, to the lack of in duc tion of tu mor re sponse, the po ten tially more radioresistant postsurgical bed due to more hypoxic tis sues, and the need for wider ra di a tion fields, to in clude the per i neal scar, if sur gery is performed by abdominoperineal re sec tion (APR). More over a post op er a tive RTCT was shown to be un able to compen sat ing for the pres ence of in volved or threat ened circumfer ential mar gins at sur gery 24 . Two im por tant ran dom ized tri als ad dressed that is sue 5, 25 . The Ger man Rec tal Can cer Trial pub lished in 2004 by Sauer et al. 5 , en rolled more that 800 pa tients and random ized pa tients pre sent ing T3-4 and/or N+ le sions (sited at less than16 cm from the anal verge) to ei ther preop er a tive RTCT (with PVI 5-Fu) ver sus post op er a tive RTCT. For pa tients in the arm un der go ing pre op er a tive treat ment, they did found lower rates of lo cal re cur rences (6% vs. 13%; p = .006), and less acute tox ic ity (27% vs. 40%; p = .001), also late tox ic ity rates were lower (14% vs. 24%; p = .012). Morever, au thors re ported a sig nif icant in crease in rates of sphincter pres er va tion (39% vs. 20%; p = .004) re spect to the base line choice by the surgeon to per form an APR.
They did not find any ben e fit for over all sur vival (OS) in one set ting com pared with the other (5-year OS: 74% vs. 76%). These re sults were later con firmed at an up date with more than 10 years of me dian fol low-up 26 .
The NSABP R-03 trial ran dom ized cT3-4 rec tal cancers pa tients (af ter in duc tion 5-Fu-based CT) to RTCT ad min is tered ei ther pre op er a tively or post op er a tively 25 . The re cruit ment of 900 pa tients was planned, but only 267 were ac tu ally ac crued (thus lim it ing the sta tis ti cal power of the study).
Pa tients in the pre op er a tive arm had sig nif i cantly improved 5-year dis ease free sur vival (65% vs. 53%; p =0.011) and a non-sig nif i cant trend of im prove ment in 5-year OS (75% vs. 66%; p=0.065).
Rates of 5-year lo cal con trol were sim i lar in the 2 arms (11%).
Re gard ing tox ic ity: in ci dence of Grade 4 tox ic ity was more fre quent in the pre op er a tive arm (33% vs. 23%, mostly re lated to di ar rhea); con versely, Grade 3 tox ic ity was less fre quent (41% vs. 50%). Sphincter pres er vation's rates im prove ment (on the ba sis of the base line eval u a tion by the sur geon) (48% vs. 39%) was not observed in this trial.
As pre vi ously men tioned, also the se lec tive use of postop er a tive RTCT to over come an ad verse post op er a tive pre sen ta tions was shown to be in fe rior to the di rect use of pre op er a tive treat ment.
In 2009 the UK Med i cal Re search Coun cil trial (MRC C07) ran dom ized 1350 pa tients to pre op er a tive RT (with SCRT ad min is ter ing 5 Gy x 5 frac tions) or to se lec tive post op er a tive RTCT (with LCRTCT ad min is ter ing 45 Gy at con ven tional frac tion ation plus con cur rent 5-Fu based chemosensibilization) 24 . Post op er a tive LCRTCT was only pro vided to pa tients with histologic rad i cal mar gins of less than 1 mm. With a me dian fol low-up of 4 years, pa tients who re ceived pre op er a tive com pared with se lective post op er a tive treat ment had sig nif i cantly lower 3-year lo cal re cur rence rates (4.4% vs. 10.6%; p<0.0001) and higher 3-year dis ease free sur vival (77.5% vs. 71.5%; p = 0.013). It should be high lighted that this was not a trial meant to com pare the SCRT to the LCRTCT ap proach, be ing the lat ter only ap plied for more ad verse pre sen ta tions, and in the sub-op ti mal post op er a tive setting.
On the ba sis of the ev i dences pro vided by these RCTs, the cur rent stan dard of multimodal in te grated ap proach to resectable rec tal can cer is rep re sented by the pre op er a tive one, as sum ma rized by In ter na tional guide lines , the NIH rec om men da tions about the use of post op er a tive RTCT stand in case of pT3 and/or N1-2 le sions 22, 27 .
Role of Pre op er a tive Ra dio ther apy in the Clin i cal In tegrated Man age ment
Pre op er a tive ra dio ther apy, ei ther in the SCRT or LCRTCT sched ule, is the cur rent stan dard ap proach to resectable (and mar gin ally resectable) rec tal can cer 11,28,2,10 . The need for an adjuvant treat ment in te grat ing the suboptimal re sults of the sur gery tech niques around '70 and early '80 29, 30 has been al ready de scribed in the pre vi ous para graph: around '90, in USA and part of the Eu rope, it lead to the choice of post op er a tive LCRTCT sched ules. In the same pe riod also some north ern Eu ropean Groups re ported the pos i tive im pact on clin i cal outcome by add ing pre op er a tive RT (adopt ing the SCRT sched ule) over sur gery alone. In par tic u lar the Swed ish Rec tal Can cer Trial, pub lished in 1997, not only confirmed a sig nif i cant de crease in lo cal re cur rence rates (as for other pre vi ous sim i lar ex pe ri ences) but also gained a sig nif i cant sur vival ben e fit over sur gery alone 31 . They ran dom ized 1168 pa tients with cT1-3 rec tal cancer to re ceive or not 25 Gy (in 5 frac tions of 5 Gy each) in 1 week, be fore un der go ing sur gery. The ex per i men tal arm showed sig nif i cantly higher lo cal con trol rates (12% vs. 27%; p <0.001) and an im prove ment in 5-year OS (58% vs. 48%; p = 0.004). An up date af ter 13 years, did con firm the sur vival ben e fit (38% vs. 30%; p =0.008) 32 . Among the over 10 ran dom ized tri als adopt ing SCRT (with out con com i tant che mo ther apy) it re mains the only one sig nif i cantly af fect ing sur vival 10, 33 . Al most con tempo rary, the North Amer i can ex pe ri ences of LCRTCT, on the ba sis of some non ran dom ized en cour ag ing ex per iment of pre op er a tive LCRTCT 34 ,were con sol i dat ing the use of pre op er a tive ap proach. Later on, the de vel op ing of the new sur gi cal ap proach rep re sented by the to tal mesorectal ex ci sion (TME), first pro posed by Heald and col leagues 35, 3 , rad i cally im proved the clin i cal out come af ter sur gery only. The lo cal re lapse rates were re duced of around 30% re spect to the pre vi ous re ports: the av erage 5 years lo cal re cur rence rates were about 5% 1, 36 , ques tion ing the need for neoadjuvant RT in it self (ir respec tively by the sched ule adopted). The sub se quent random ized trial pub lished by Kapiteijn et al. 6 , high lighted the ben e fit in term of lo cal con trol al though not on survival, de rived by add ing neoadjuvant ra dio ther apy even to an op ti mal sur gi cal pro ce dure. That multicenter random ized trial (com monly also known as "Dutch trial") ap plied a cer tif i ca tion of the qual ity for the sur gery per -formed in the study. The de sign of that trial faced TME-cer ti fied sur gery alone to the same pro ce dure preceded by neoadjuvant SCRT. Over 1800 pa tients pre senting Stage II and III resectable rec tal can cers were enrolled. The 2-year lo cal con trol sig nif i cantly fa vored the arm of in te grated ap proach (2.4% vs 8.2%, p<0.001), while sur vival did not dif fer (82% vs 8.8%). On the other hand also the su pe ri or ity of long course radiochemotherapy ver sus long course ra dio ther apy alone in the pre op er a tive set ting was con firmed by two ran dom ized tri als pub lished in 2006, thus in "TME-era" 37, 38 . The Euro pean Or ga ni za tion for Re search and Treat ment of Cancer (EORTC) trial 22921 ran dom ized over 1000 pa tients into 4 arms The arms ad min is ter ing LCRTCT re ported sig nif i cantly higher lo cal con trol rates (8% to 10% vs. 17%; p <0.001) but no dif fer ence in the 5-year OS (65%), and sim i larly to other ex pe ri ences, also at the up dated re port af ter 10 year of fol low-up the ev i dence did not var ied 39 .
In the same year a less com plex RCT per formed by the Fédération Francophone de la Cancérologie Di ges tive (FFCD 9203) eval u ated the same is sue. They ran dom ized 742 pa tients to ei ther pre op er a tive long course RT (de liver ing 45 Gy with con ven tional frac tion ation) with 5-Fu-based con com i tant CT or to the same RT sched ule with out con com i tant CT 37 . Like in the sim i lar pre vi ous ran dom ized ex per i ment, reduced lo cal fail ure rates (8% vs 17%; p <0.05) but no sur vival ben e fit (68% vs. 67%) were re ported.
It should be spec i fied that even though both these 2 RCTs have been per formed in the "TME-era" that was rec om mended but not man da tory thus per formed in reduced per cent ages of the casistics. Any way one of the main is sues in ves ti gated (i.e. the su pe ri or ity of con current long course radiochemotherapy over long course radio ther apy alone) main tain its global sig nif i cance.
More over an in ter est ing par al lel ism in the find ing of a sig nif i cantly higher rate of pCR in the LCRTCT rather than in the RT only group was ad dressed by both these RCTs.
About the last RCTs men tioned, it is im por tant to first of all high light that the "Dutch trial" rep re sents the ev idence of sig nif i cantly worth in te gra tion of sur gery with RT in it self rather than an in di ca tion to the spe cific use of SCRT 6 . Sim i larly the RCTs from Bos set et al. and Gerard et al. 37, 38 only rep re sent the ba sis to re mark the su pe ri or ity of radiochemotherapy also in the pre op er a tive set ting when the long course ap proach is cho sen: only RCTs di rectly com par ing SCRT and LCRTCT have deep ened the ques tion on the sched ule to be pre ferred.
The global ev i dence ba sis from the ran dom ized trial reported seem to sum ma rize that: the mod ern sur gery for rec tal can cer must be per formed with a TME pro ce dure 35, 3 ; the in te gra tion of TME-sur gery with ra dio ther apy is ben e fi cial, in par tic u lar to im prove lo cal con trol and must be adopted in the pre op er a tive set ting to re duce tox ic ity and comorbidities 6, 26 . In the mod ern "TME era", no random ized trial of multimodal ap proach, ei ther SCRT or LCRTCT re ported a sur vival ben e fit as sin gle study; the best pre op er a tive sched ule to ap ply has to still be de termined.
Def i ni tion of the op ti mal Pre op er a tive sched ule of Ra diother apy: Short Course Ra dio ther apy alone ver sus Long Course Radiochemotherapy
As Bujko sum ma rized in a re view, there is still not enough ev i dence ba sis to de ter mine what pre op er a tive ap proach of RT is def i nitely su pe rior be tween SCRT and LCRTCT . As Minsky high lighted in the same con text, there are dif fer ent rea sons that lead to the two ba sic approaches of pre op er a tive RT in the re spec tive ma jor ar eas of dif fu sion: SCRT in the north of Eu rope, and LCRTCT in USA and mid dle/South Eu rope 41 . That in clude the trend of re search that we de scribed in the pre vi ous paragraphs: in USA the com bined use of RTCT in the post oper a tive set ting was shifted into the pre op er a tive one by the ev i dences pro vided from RCT, whilst in north ern Europe the ad min is tra tion of CT com bined to RT was felt as more in ves ti ga tional, pre fer ring to re fer to dif fer ent forms of in ten si fi ca tions of the bi o log i cal ef fi cacy (as by hypofractionation. The choice to en hance the dif fer ent po ten tials of one or the other ap proach can ad dress the sched ule to pre fer in rou tine prac tice or in spe cific sit u ations (e.g. the higher pro to col ad her ence or less clin i cal de mand of SCRT ver sus the safe com bi na tion with chemo ther apy or the po ten tial of downstaging the le sion of the LCRTCT). Fi nally the dif fer ent types of Na tional reim burse ment pol i cies could also play a role. All these dif fer ences are sum ma rized by the cer tain range of dif ferences among the rec om men da tions re ported by dif fer ent Na tional Guide lines 2 . As gen eral con sid er ation: the al ready men tioned random ized tri als ap ply ing SC (Swed ish trial or Dutch trial) or LCRTCT (Ger man trial from Sauer et al.) are not directly or undirectly com pa ra ble about re sults; first (ob viously) be cause they did not ran dom ize one ap proach versus the other, sec ond, be cause pa tients se lected for SCRT in cluded pa tients with lower Stages (mostly cT1-3), while the vast ma jor ity of the pa tients ac crued in the German trial had stage cT3 and/or N+ 10 . Two RCTs di rectly com pared SCRT to LCRTCT failing in re veal ing a de fin i tive an swer. The Pol ish trial from Bujko et al. ran dom ized 312 pa tients with cT3 rec tal cancers to SCRT plus im me di ate sur gery (i.e. 1 week later) ver sus LCRTCT with 5-Fu-based con com i tant che mother apy and de layed sur gery (i.e.: 4-6 weeks af ter) . No sig nif i cant dif fer ences in lo cal re cur rence (14% vs. 9%), dis ease free sur vival (56% vs. 58%) and 4-year sur vival (66% vs. 67%) rates have been found.
In ter est ingly, the LCRTCT arm re corded an higher pCR rate (16% vs. 1%) and a lower in ci dence of pos i tive ra dial mar gins (4% vs. 13%, p=0.017).
An Aus tra lian trial ran dom ized 326 rec tal can cer patients (cT3N+/-) to SCRT ver sus LCRTCT. Each arm admin is tered post op er a tive che mo ther apy 43 . At a me dian fol low-up of 5.9 years dis tant fail ure and over all sur vival rates did not dif fer.
Other ran dom ized tri als test ing the same point are ongo ing. A study from a Ger man group (also named as "Berlin" Trial) will also in clude T2 N1-3 pa tients; adjuvant chemo-ther apy will be man da tory for all the patients, and a high num ber of pa tients will be sought 44 . The Stock holm III study is a three-arm RCT com par ing long-course RT (with out con com i tant che mo ther apy) with de layed sur gery, SCRT with im me di ate sur gery, and SCRT with de layed sur gery 45 . The last arm is in tended to as sess the po ten tial of short-course ra dio ther apy to ob tain pCR (mit i gat ing one of the dis ad van tages of SCRT): in the pub lished in terim anal y sis the short-course arm followed by de layed sur gery had 12.5% pCR com pared with 0.8% in the SCRT arm with im me di ate sur gery. Fi nal results of the last 2 men tioned tri als are still pend ing.
Open Ques tions on SCRT and LCRTCT: how to im prove their re sults?
Fi nal con sid er ations about SCRT and LCRTCT should de scribe the ap proaches to im prove each re sult by enhanc ing the re spec tive po ten tials or re duc ing the dis advan tages.
The Stock holm III trial tries to in crease the pCR rates of SCRT by en larg ing the de lay be fore sur gery: the achieve ment of pCR was widely re ported as as so ci ated to sig nif i cantly better sur vival out come 46 , a re cent pooled anal y sis based on data de rived from the ma jor ran domized trial also con firmed that 47 , that is usu ally sig nif icantly more ob tain able by the use of LCRTCT; more over the ex cel lent out come for pa tient achiev ing a pCR lead to the ex pe ri ences of wait-and-see pol icy of avoid ance of sur gery, with in ter est ing pre lim i nary re sults to be fur ther eval u ated in larger se ries 4, 48 . The in terim re sults seem to con firm that, but it should be stressed that such re sults can not be di rectly com pared to the long course arm since that lacks the con com i tant radiosensibilization in the Stock holm III. The RAPIDO trial was al ready men tioned, look ing at the po ten tial to com bine SCRT with che mother apy. On the other hand, re search ers com monly ap plying LCRTCT try to en hance its po ten tial to clas si cally ob tain higher pCR rates and re duce CRM+ by op ti miz ing the con com i tant drug as so ci a tion. In this di rec tion attempts to in clude new drugs like Irinotecan 49, 50 or bi olog i cal mo lec u lar tar geted ther a pies like Bevacizumab 51 in Phase I -II ran dom ized tri als re ported con flict ing results. New in ter est ing is sues were re cently re ported about the use of Cetuximab 52 . The con com i tant as so ci a tion of LCRTCT with Oxaliplatin was ad dressed over last years. Five ran dom ized tri als have ex am ined the im pact of ad dition of oxaliplatin to 5-FU or capecitabine based RTCT on re sponse rates and acute tox ic ity in pa tients with cT3-4 and/N+ rec tal can cer 53, 54, 55, 56, 57 . With the ex cep tion of the Ger man CAO/ARO/AIO-04, the other RCT showed in creased acute tox ic ity with out im prove ment of the pCR rates: the con clu sion should be to not in clude oxaliplatin with con ven tional LCRTCT reg i mens, al least un til de fin i tive data on lo cal con trol and sur vival will be avail able. In ter est ingly in one of these, the NSABP R-04, was also con firmed in ran dom ized trial set ting the non-in fe ri or ity of the use of oral Capecitabine in stead of in fu sion 5-Fu 57 . Sim i larly to some SCRT new ap proaches, a se quen tial CT-ad min is tra tion was at tempted into LCRTCT schedules. Gar cia-Aguilar et al. per formed a phase II ran domized trial on 144 pa tients with cN+ rec tal can cer 58 . One arm ad min is tered pre op er a tive RTCT (50.4 Gy + 5-Fu con com i tant CT) fol lowed by sur gery (af ter 6 weeks), the ex per i men tal one ad min is tered the same pre op er a tive sched ule, but for pa tient pre sent ing a clin i cal re sponse, added mFOLFOX6 fol lowed by sur gery (11 weeks later). The pCR rate was in creased in the mFOLFOX arm (25% vs. 18%) with no as so ci ated in crease in post op er a tive com pli ca tions (40% in each arm).
Lastly, the ran dom ized trial IN TER ACT ad dressed the is sue to intensificate the bi o log i cal ef fect by de liv er ing a con com i tant boost to the pri mary le sion rather that by inten si fy ing the con com i tant drug ad min is tra tion. The prelim i nary re sults con firmed an ac cept able toxic pro file for the con com i tant boost arm, with a rate of pCR at the top bound aries of the lit er a ture re ports.
CON CLU SIONS
Ran dom ized tri als re ported the most im por tant ev idence ba sis cur rently avail able about the in te grated manage ment of rec tal can cer tu mors. RCTs also seem fun damen tal to sum ma rize the more ob jec tive con clu sions in term of shared stan dards of care, but also to ad dress the fu ture line of re search for op ti mize sur vival out comes. A re cent pooled anal y sis per formed of data de rived by RCTs avail able con firmed the pos i tive im pact by pre oper a tive ra dio ther apy into the in te grated man age ment of rec tal can cer. This im pact seemed stron ger for pa tients achiev ing pCR (more fre quently af ter LCRTCT). In the mod ern era, be ing avail able tech ni cal ad van tages like the learn ing mod els to elab o rate data de rived by large da tabases, and with an al ways in creas ing amount of new param e ters upfront in di vid u at ing the po ten tial out comes, or pre dict ing re sponse to ther a pies (like microRNA level or cir cu lat ing tu mor cells dos age, new mo lec u lar im ag ing mo dal i ties or elab o ra tion of soft ware-driven im age data) it is im por tant to re fer to RCTs struc tured on rig or ous basis, and keep ing into ac count new surrogative end points to speed up the re search pro cesses.
SUM MARY ŠTA MOŽEMO NAUÈITI IZ RANDOMIZIRANIH STUDIJA O KARCINOMU REKTUMA I U ŠTA MOŽEMO VEROVATI
Rezultati leèenja karcinoma rektuma su se znaèajno poboljšali u poslednjih skoro èetrdeset godina, zahvaljujuaei progresivnom razvoju novih integrisanih terapijskih moguaenosti.
Pa ipak, neophodna je optimizacija rezultata da bi se poveaeao još uvek sub-optimalni nivo preživljavanja. Nekolika nacionalna i meðunarodna vodièa nude najbolje opcije tretmana na bazi procene podataka iz lit er a ture.
Meðutim, još uvek postoji izvestan stepen neslaganja, posebno oko prednosti preoperativnog RT tretmana.
Randomizirani trajali èine glavnu okosnicu i najvažnije sredstvo za nauèni sce nario: definisati moguaee uspostavljanje standarda leèenja ili sugerirati najviše obeaeavajuaee pristupe cilju istraživanja i u tom smislu usmeriti napore klinièara i istraživaèa.
Ovaj rad je pretežno usmeren na rezultate iz randomizirane klinièke studije koja se odnosi na multimodalni integrisani tretman karcinoma rektuma. On je fokusiran uporedo na lokalno uznapredovali (LA) primarno neresektabilni (UR) i na resektabilni karcinom rektuma; biaee navedene i izvesne relevantne ne-randomizirane studije.
Kljuène reèi karcinom rektuma, kombinovani tretman, preoeprativna radioterapija, hirurgija, postoperativna radioterapija, hemoterapija
